- Home
- NEOV vs INZY Comparison
NEOV vs INZY Comparison
Compare NEOV & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEOV
- INZY
- Stock Information
- Founded
- NEOV 2018
- INZY 2015
- Country
- NEOV United States
- INZY United States
- Employees
- NEOV N/A
- INZY N/A
- Industry
- NEOV Industrial Machinery/Components
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- NEOV Miscellaneous
- INZY Health Care
- Exchange
- NEOV Nasdaq
- INZY Nasdaq
- Market Cap
- NEOV 181.8M
- INZY 188.2M
- IPO Year
- NEOV N/A
- INZY 2020
- Fundamental
- Price
- NEOV $3.27
- INZY $1.42
- Analyst Decision
- NEOV Strong Buy
- INZY Strong Buy
- Analyst Count
- NEOV 1
- INZY 8
- Target Price
- NEOV $7.50
- INZY $17.75
- AVG Volume (30 Days)
- NEOV 314.7K
- INZY 1.0M
- Earning Date
- NEOV 02-11-2025
- INZY 03-11-2025
- Dividend Yield
- NEOV N/A
- INZY N/A
- EPS Growth
- NEOV N/A
- INZY N/A
- EPS
- NEOV N/A
- INZY N/A
- Revenue
- NEOV $2,471,178.00
- INZY N/A
- Revenue This Year
- NEOV $85.10
- INZY N/A
- Revenue Next Year
- NEOV $281.25
- INZY N/A
- P/E Ratio
- NEOV N/A
- INZY N/A
- Revenue Growth
- NEOV N/A
- INZY N/A
- 52 Week Low
- NEOV $0.63
- INZY $1.24
- 52 Week High
- NEOV $6.11
- INZY $7.80
- Technical
- Relative Strength Index (RSI)
- NEOV 37.47
- INZY 31.52
- Support Level
- NEOV $3.27
- INZY $1.35
- Resistance Level
- NEOV $3.85
- INZY $1.45
- Average True Range (ATR)
- NEOV 0.33
- INZY 0.12
- MACD
- NEOV -0.04
- INZY 0.04
- Stochastic Oscillator
- NEOV 13.12
- INZY 43.42
About NEOV NeoVolta Inc.
NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.